Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1985 2
1986 3
1987 5
1988 6
1989 8
1990 8
1991 5
1992 1
1993 6
1994 9
1995 8
1996 3
1997 11
1998 14
1999 7
2000 2
2001 3
2002 1
2003 10
2004 4
2005 1
2006 1
2007 7
2008 2
2009 5
2010 16
2011 14
2012 18
2013 15
2014 16
2015 19
2016 19
2017 14
2018 16
2019 17
2020 17
2021 13
2022 10
2023 7
2024 11
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Results by year

Filters applied: . Clear all
Page 1
Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer.
Dadgar H, Pashazadeh A, Norouzbeigi N, Assadi M, Al-Balooshi B, Baum RP, Al-Ibraheem A, Haidar M, Beheshti M, Geramifar P, Vali R, Mohammadi S, Dash S, Malasani V, Cimini A, Ricci M, Esmail AA, Murad S, Marafi F, Treglia G, Khalaf AN, Anwar FM, Usmani S, Omar Y, Muhsin H, Tyurin IE, Zakhary A, Al-Sebaie S, Cortes DM, AlHashim M, Arabi H, Zaidi H. Dadgar H, et al. Among authors: baum rp. Theranostics. 2025 Mar 18;15(10):4368-4397. doi: 10.7150/thno.107963. eCollection 2025. Theranostics. 2025. PMID: 40225563 Free PMC article. Review.
Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders.
Maharaj M, Perrone E, Wirtz RM, Heslop L, Govender T, Korowlay NA, Ghai K, Parkar T, Baum RP. Maharaj M, et al. Among authors: baum rp. Cancers (Basel). 2025 Jan 31;17(3):476. doi: 10.3390/cancers17030476. Cancers (Basel). 2025. PMID: 39941843 Free PMC article.
Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.
Perrone E, Giordano A, Calcagni ML, Leccisotti L, Moretti R, Eismant A, Ghai K, Parkar T, Mishra A, Heidenreich A, Wirtz RM, Müller J, Greifenstein L, Baum RP. Perrone E, et al. Among authors: baum rp. Cancers (Basel). 2025 Jan 26;17(3):405. doi: 10.3390/cancers17030405. Cancers (Basel). 2025. PMID: 39941774 Free PMC article.
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides.
Baum RP, Novruzov E, Zhao T, Greifenstein L, Jakobsson V, Perrone E, Mishra A, Eismant A, Ghai K, Klein O, Jaeschke B, Benz-Zils D, Cardinale J, Mori Y, Giesel FL, Zhang J. Baum RP, et al. Semin Nucl Med. 2024 Jul;54(4):537-556. doi: 10.1053/j.semnuclmed.2024.05.010. Epub 2024 Jul 16. Semin Nucl Med. 2024. PMID: 39019653 Review.
337 results